Infertility Clinical Trial
Official title:
Ovarian Stimulation Single Injection Elonva- The OSSIE Study
We would like to propose that it may be possible to use a solitary dose of Elonva (corifollitrophin alpha) as the sole gonadotrophin (FSH) stimulant for the vast majority of women undergoing IVF, assuming that it is possible that "coasting" (withholding short acting rFSH) from day 8 of the stimulation until trigger/ oocyte retrieval will still result in a significant number of mature oocytes being produced and an acceptable pregnancy rate.
Elonva (corifollitrophin alfa) has been shown to be a very effective rFSH stimulant for
Controlled Ovarian Hyperstimulation (COH) in the setting of IVF treatment. Its long duration
of action (7 days) results in a significant reduction in the number of COH stimulation
injections (average of 3 injections v 9 injections in the traditional "short acting" r FSH
COH), with 30% of patients requiring only a single Elonva injection for their COH (Engage
study, Devroey et al 2009). It is assumed that a reduction in the number of required COH
injections will have the advantages of improved patient acceptability and better compliance
due to a reduction in room for error. Despite these advantages the clinical uptake of Elonva
has been slow due to 2 principal concerns among clinicians:
1. A tendency for Elonva COH to result in a higher ovarian response with increased risk of
Ovarian Hyper-Stimulation Syndrome (OHSS). While this risk of OHSS was not
statistically significant in the pivotal Engage study, there was still a numerically
greater chance of OHSS and a greater chance of the IVF cycle being cancelled due to
OHSS risk in the Elonva arm compared to the traditional Puregon arm. Since women at
high risk of OHSS were excluded from the Engage study, clinicians perceive that the
risk of OHSS is likely to be significantly greater in the more heterogeneous general
clinical population. Whether this is a correct assumption is still up for debate, but
it is a perceived issue with the existing Elonva protocol that must be addressed if
Elonva is to become used widely as a COH stimulant.
2. According to the Engage and Ensure studies, the majority (70%) of women using Elonva
require "top up"short acting Puregon rFSH, with an average of 2 doses being required
before the patients reach the criteria for triggering and oocyte retrieval. As a result
clinics are required to teach two different injection protocols, increasing the time
required to educate the patient and possibly increasing the risk of confusion. The
ability to deliver a solitary COH stimulant without the need for any "top up" Puregon
would be a major advantage.
Rationale We would like to propose that it may be possible to use a solitary dose of Elonva
as the sole COS rFSH stimulant for the vast majority of women undergoing IVF, assuming that
it is possible that "coasting" (withholding short acting rFSH) from day 8 of the stimulation
until trigger/ oocyte retrieval will still result in a significant number of mature oocytes
being produced.
In the setting of OHSS it is common practice to withhold any further rFSH stimulant towards
the end of the COS process. It is generally accepted that medium size follicles of 14 mm or
greater will continue to develop to maturity in the absence of rFSH stimulation, while
smaller follicles will regress. This has the therapeutic advantage of reducing estradiol
levels and OHSS risk in women at high risk of OHSS. With this coasting physiology in mind,
we propose that provided a single injection of Elonva can result in a significant number of
follicles being 14 mm or greater by day 8 of stimulation, further rFSH will not be required.
Results from the Engage study (Doody et al 2011) reveal that by day 8 of stimulation on
average there were 5.1 follicles of 15 mm or greater. Therefore even if no further "top up"
rFSH was given from day 8, one could expect to get at least 5 mature oocytes from an oocyte
retrieval triggered by hCG in the next 2 days. While 5 mature oocytes is significantly less
than what was produced by the traditional Elonva protocol using additional rFSH (average
10.8 in the Engage study, 10.7 in the Ensure study), this could be perceived as a
significant advantage since it will likely result in a significant reduction in OHSS risk, a
perceived problem with the traditional Elonva protocol. If we assume a 70% fertilization
rate and that approximately half of all embryos are of good quality by day 4/5 of culture,
the production of > 3 mature oocytes should ensure the generation of at least one good
quality embryo for transfer with a good chance of pregnancy. This type of low impact
stimulation is likely to be very popular in Europe and Australia where clinicians already
accept the benefits of mild COS.
In summary, if we are able to provide evidence in this pilot study that a single injection
of Elonva can result in the majority of women reaching oocyte retrieval with the production
of at least 3 mature oocytes, while giving good fresh embryo transfer pregnancy rates and no
OHSS, the coasting Elonva protocol may become a significant clinical protocol for low impact
COS in the future.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A |